Propanc Biopharma Inc (NASDAQ:PPCB) Sees Significant Increase in Short Interest

Propanc Biopharma Inc (NASDAQ:PPCB) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 335,967 shares, an increase of 497.2% from the August 15th total of 56,255 shares. Currently, 20.7% of the company’s shares are sold short. Based on an average trading volume of 9,115,538 shares, the days-to-cover ratio is currently 0.0 days.

Propanc Biopharma Price Performance

PPCB traded down $0.02 during trading on Friday, hitting $0.92. 225,040 shares of the stock traded hands, compared to its average volume of 5,237,049. The firm has a market capitalization of $2.10 million, a P/E ratio of -0.04 and a beta of 3.52. Propanc Biopharma has a 12-month low of $0.87 and a 12-month high of $62.50. The firm has a 50-day moving average of $1.28 and a 200 day moving average of $2.11.

Propanc Biopharma announced that its board has initiated a stock buyback program on Thursday, June 11th that allows the company to repurchase $5.00 million in outstanding shares. This repurchase authorization allows the company to purchase up to 162.3% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Propanc Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 26th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Institutional Investors Weigh In On Propanc Biopharma

An institutional investor recently bought a new position in Propanc Biopharma stock. Virtu Financial LLC acquired a new position in Propanc Biopharma Inc (NASDAQ:PPCB) during the third quarter, according to its most recent filing with the SEC. The firm acquired 41,677 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned about 0.33% of Propanc Biopharma as of its most recent filing with the SEC.

Propanc Biopharma Company Profile

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.